Making treatment guideline recommendations in chronic kidney disease and type 2 diabetes more accessible to primary care providers in the United States

References

• U.S. Renal Data System. 2022 USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2022.
   Google Scholar
• Centers for Disease Control and Prevention. Make the connection. [ cited 2023 Jul 19]. Available from: https://www.cdc.gov/kidneydisease/prevention-risk/make-the-connection.html
   Google Scholar
• Kobo O, Abramov D, Davies S, et al. CKD-associated cardiovascular mortality in the United States: temporal trends from 1999 to 2020. Kidney Med. 2023;5(3):100597. doi: 10.1016/j.xkme.2022.100597
   PubMedGoogle Scholar
• Sud M, Tangri N, Pintilie M, et al. Progression to stage 4 chronic kidney disease and death, acute kidney injury and hospitalization risk: a retrospective cohort study. Nephrol Dial Transplant. 2016;31(7):1122–1130. doi: 10.1093/ndt/gfv389
   PubMed Web of Science ®Google Scholar
• Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic Health: a presidential advisory from the American heart association. Circulation. [2023 Nov 14];148(20):1606–1635. doi: 10.1161/CIR.0000000000001184
   PubMed Web of Science ®Google Scholar
• National Institutes of Diabetes and Digestive and Kidney Diseases. Slow progression & reduce complications. [cited 2023 Jun 1]. Available from: https://www.niddk.nih.gov/health-information/professionals/clinical-tools-patient-management/kidney-disease/identify-manage-patients/manage-ckd/slow-progression-reduce-complications
   Google Scholar
• ElSayed NA, Aleppo G, Bannuru RR American Diabetes Association Professional Practice C. 11. Chronic kidney disease and risk management: standards of care in diabetes—2024. Diabetes Care. [2024 Jan 1];47(Suppl 1):S219–S230. doi: 10.2337/dc24-S011
   PubMedGoogle Scholar
• Stevens PE, Ahmed SB, Carrero JJ Kidney Disease: Improving Global Outcomes CKDWG. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International. 2024 Apr;105(4):S117–S314. doi: 10.1016/j.kint.2023.10.018
   PubMedGoogle Scholar
• Rossing P, Caramori ML, Chan JCN Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5):S1–S127. doi: 10.1016/j.kint.2022.06.008
   PubMed Web of Science ®Google Scholar
• Kelepouris E, St Peter W, Neumiller JJ, et al. Optimizing multidisciplinary care of patients with chronic kidney disease and type 2 diabetes mellitus. Diabetes Ther. 2023;14(7):1111–1136. doi: 10.1007/s13300-023-01416-2
   PubMed Web of Science ®Google Scholar
• Vu A, Nicholas SB, Waterman AD, et al. “Positive kidney health”: implementation and design of a pharmacist-led intervention for patients at risk for development or progression of chronic kidney disease. J Am Pharm Assoc (2003). 2023 Mar;63(2):681–689. doi: 10.1016/j.japh.2022.11.007
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Bannuru RR American Diabetes Association Professional Practice C. Introduction and methodology: standards of care in diabetes—2024. Diabetes Care. [2024 Jan 1];47(Supplement_1):S1–S4. doi: 10.2337/dc24-SINT
   PubMedGoogle Scholar
• Estrella MM, Jaar BG, Cavanaugh KL, et al. Perceptions and use of the national kidney foundation KDOQI guidelines: a survey of U.S. renal healthcare providers. BMC Nephrol. 2013;14(1):230. doi: 10.1186/1471-2369-14-230
   PubMedGoogle Scholar
• Sperati CJ, Soman S, Agrawal V, et al. Primary care physicians’ perceptions of barriers and facilitators to management of chronic kidney disease: a mixed methods study. PLOS ONE. 2019;14(8):e0221325. doi: 10.1371/journal.pone.0221325
   PubMed Web of Science ®Google Scholar
• de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO). Kidney Int. 2022;102(5):974–989. doi: 10.1016/j.kint.2022.08.012
   PubMed Web of Science ®Google Scholar
• Vest BM, York TR, Sand J, et al. Chronic kidney disease guideline implementation in primary care: a qualitative report from the translate ckd study. J Am Board Fam Med. 2015;28(5):624–631. doi: 10.3122/jabfm.2015.05.150070
   PubMed Web of Science ®Google Scholar
• Chu CD, Powe NR, Shlipak MG, et al. Albuminuria testing and nephrology care among insured US adults with chronic kidney disease: a missed opportunity. BMC Prim Care. 2022;23(1):299. doi: 10.1186/s12875-022-01910-9
   PubMedGoogle Scholar
• Greer RC, Liu Y, Cavanaugh K, et al. Primary care physicians’ perceived barriers to nephrology referral and co-management of patients with CKD: a qualitative study. J Gen Intern Med. 2019;34(7):1228–1235. doi: 10.1007/s11606-019-04975-y
   PubMed Web of Science ®Google Scholar
• Rikin S, Deccy S, Zhang C, et al. Care gaps in sodium-glucose cotransporter-2 inhibitor and renin angiotensin system inhibitor prescriptions for patients with diabetic kidney disease. J Gen Intern Med. 2023;38(7):1599–1605. doi: 10.1007/s11606-022-07863-0
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229. doi: 10.1056/NEJMoa2025845
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. INVOKANA (canagliflozin) tablets, for oral use. 2020 [2023 Sep 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204042s036lbl.pdf
   Google Scholar
• Food and Drug Administration. FARXIGA (dapagliflozin) tablets, for oral use. 2021 [cited 2023 Sep 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202293s024lbl.pdf
   Google Scholar
• Food and Drug Administration. JARDIANCE (empagliflozin tablets), for oral use. 2023 Sep 07. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s040lbl.pdf
   Google Scholar
• Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263. doi: 10.1056/NEJMoa2110956
   PubMed Web of Science ®Google Scholar
• Rossing P, Anker SD, Filippatos G, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care. 2022 Dec 1;45(12):2991–2998. doi: 10.2337/dc22-0294
   PubMed Web of Science ®Google Scholar
• Gragnano F, De Sio V, Calabro P. FLOW trial stopped early due to evidence of renal protection with semaglutide. Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):7–9. doi: 10.1093/ehjcvp/pvad080
   PubMed Web of Science ®Google Scholar
• Rossing P, Baeres FMM, Bakris G, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023 Aug 31;38(9):2041–2051. doi: 10.1093/ndt/gfad009
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022–2031. doi: 10.1161/CIRCULATIONAHA.118.038868
   PubMed Web of Science ®Google Scholar
• Jeong SJ, Lee SE, Shin DH, et al. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study. BMC Nephrol. 2021;22(1):177. doi: 10.1186/s12882-021-02381-3
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152–161. doi: 10.1093/eurheartj/ehaa736
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. INSPRA (eplerenone) tablets. [cited 2021 Aug 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021437s006lbl.pdf
   Google Scholar
• Food and Drug Administration. ALDACTONE® (spironolactone) tablets for oral use. [cited 2023 Aug 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012151s075lbl.pdf
   Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709–717. doi: 10.1056/NEJM199909023411001
   PubMed Web of Science ®Google Scholar
• Folkerts K, Petruski-Ivleva N, Comerford E, et al. Adherence to chronic kidney disease screening guidelines among patients with type 2 diabetes in a US administrative claims database. Mayo Clin Proc. 2021;96(4):975–986. doi: 10.1016/j.mayocp.2020.07.037
   PubMed Web of Science ®Google Scholar
• Allen D, Harkins KJ. Too much guidance? Lancet. 2005;365(9473):1768. doi: 10.1016/S0140-6736(05)66578-6
   PubMed Web of Science ®Google Scholar
• Gaitonde DY, Cook DL, Rivera IM. Chronic kidney disease: detection and evaluation. Am Fam Physician. 2017;96(12):776–783.
   PubMed Web of Science ®Google Scholar
• Moyer VA, Force USPST. Screening for chronic kidney disease: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2012;157(8):567–570. doi: 10.7326/0003-4819-157-8-201210160-00533
   PubMed Web of Science ®Google Scholar
• Qaseem A, Hopkins RH Jr., Sweet DE, et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159(11):770–847. doi: 10.7326/0003-4819-159-11-201312030-00009
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. All-cause mortality by eGFR, including dialysis and transplant patients. [cited 2023 Nov 2]. Available from: https://nccd.cdc.gov/CKD/detail.aspx?Qnum=Q185
   Google Scholar
• Hawthorne G, Lightfoot CJ, Smith AC, et al. Multimorbidity prevalence and patterns in chronic kidney disease: findings from an observational multicentre UK cohort study. Int Urol Nephrol. 2023;55(8):2047–2057. doi: 10.1007/s11255-023-03516-1
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Chronic kidney disease in the United States. 2023 [cited 2023 Jul 20]. Available from: https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html
   Google Scholar
• American Diabetes Association. DiabetesPro. [cited 2023 Oct 6]. Available from: https://professional.diabetes.org/
   Google Scholar
• Kidney Disease: Improving Global Outcomes. Global science. Local change. [cited 2023 Oct 6]. Available from: https://kdigo.org/
   Google Scholar
• Cheung AK, Chang TI, Cushman WC Kidney Disease: Improving Global Outcomes Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3):S1–S87. doi: 10.1016/j.kint.2020.11.003
   PubMed Web of Science ®Google Scholar
• Kidney disease: improving global outcomes. KDIGO Mobile. [cited 2023 Jul 20]. Available from: https://apps.apple.com/us/app/kdigo-mobile/id1137973979
   Google Scholar
• American Diabetes Association. ADA standards of care. [cited 2023 Jul 20]. Available from: https://apps.apple.com/us/app/ada-standards-of-care/id529516990
   Google Scholar
• ElSayed NA, Baig A, Bradley S American Diabetes Association Primary Care Advisory Group. Introduction: standards of care in diabetes—2024 abridged for primary care professionals. Clin Diabetes. 2024;42(2):181–181. doi: 10.2337/cd24-aint
   PubMedGoogle Scholar
• Kidney Disease: Improving Global Outcomes. Resources. [cited 2023 Jun 1]. Available from: https://kdigo.org/resources/
   Google Scholar
• Kidney Disease: Improving Global Outcomes. Diabetes in CKD: visual guidelines. [cited 2023 Jun 1]. Available from: https://client.globaldata.com/browse/
   Google Scholar
• Kidney Disease: Improving Global Outcomes. Infographics. [cited 2023 Jul 20]. Available from: https://kdigo.org/infographics/
   Google Scholar
• American Diabetes Association. Podcasts. [cited 2023 Nov 2]. Available from: https://professional.diabetes.org/landing/podcast
   Google Scholar
• American Diabetes Association. Standards of care updates. [cited 2023 Sep 20]. Available from: https://professional.diabetes.org/content-page/living-standards-update
   Google Scholar
• Nicholas SB, Wright EE, Billings LK, et al. Living with chronic kidney disease and type 2 diabetes mellitus: the patient and clinician perspective. Adv Ther. 2023;40(1):1–18. doi: 10.1007/s12325-022-02325-9
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. eGFR calculators. [cited 2023 Jul 20]. Available from: https://apps.apple.com/us/app/egfr-calculators/id483182385
   Google Scholar
• MD Aware LLC. Mdcalc medical calculator. [cited 2023 Jul 20]. Available from: https://apps.apple.com/us/app/mdcalc-medical-calculators-decision-support/id1001640662
   Google Scholar
• Medscape. Medscape app. [cited 2023 Sep 20]. Available from: https://www.medscape.com/public/medscapeapp
   Google Scholar
• American Gastroenterological Association. AGA NASH app. [ cited 2023 Aug 2]. Available from: https://nash.gastro.org/app
   Google Scholar
• Walters Kluwer. UpToDate: industry-leading clinical decision support. [cited 2023 Nov 2]. Available from: https://www.wolterskluwer.com/en/solutions/uptodate
   Google Scholar
• UpToDate Inc. UpToDate app. [cited 2023 Sep 20]. Available from: https://apps.apple.com/gb/app/uptodate/id334265345
   Google Scholar
• Litvin CB, Nietert PJ, Jenkins RG, et al. Translating CKD research into primary care practice: a group-randomized study. J Gen Intern Med. 2020;35(5):1435–1443. doi: 10.1007/s11606-019-05353-4
   PubMed Web of Science ®Google Scholar
• Tapuria A, Porat T, Kalra D, et al. Impact of patient access to their electronic health record: systematic review. Inform Health Soc Care. 2021 Jun 2;46(2):194–206. doi: 10.1080/17538157.2021.1879810
   Web of Science ®Google Scholar
• Norton JM, Ali K, Jurkovitz CT, et al. Development and validation of a pragmatic electronic phenotype for CKD. Clin J Am Soc Nephrol. 2019;14(9):1306–1314. doi: 10.2215/CJN.00360119
   PubMed Web of Science ®Google Scholar
• Peralta CA, Livaudais-Toman J, Stebbins M, et al. Electronic decision support for management of CKD in primary care: a pragmatic randomized trial. Am J Kidney Dis. 2020;76(5):636–644. doi: 10.1053/j.ajkd.2020.05.013
   PubMed Web of Science ®Google Scholar